MA49570A - Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak - Google Patents

Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak

Info

Publication number
MA49570A
MA49570A MA049570A MA49570A MA49570A MA 49570 A MA49570 A MA 49570A MA 049570 A MA049570 A MA 049570A MA 49570 A MA49570 A MA 49570A MA 49570 A MA49570 A MA 49570A
Authority
MA
Morocco
Prior art keywords
pyrazolo
compounds used
jak inhibitors
bicyclic compounds
triazolo
Prior art date
Application number
MA049570A
Other languages
English (en)
French (fr)
Inventor
Marta Dabros
Erik Fenster
Breena Fraga
Tom M Lam
Mandy Loo
Robert Murray Mckinnell
Jerry Nzerem
Anthony Francesco Palermo
Miroslav Rapta
Venkat R Thalladi
Diana Jin Wang
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MA49570A publication Critical patent/MA49570A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049570A 2017-08-01 2018-07-31 Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak MA49570A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762539642P 2017-08-01 2017-08-01

Publications (1)

Publication Number Publication Date
MA49570A true MA49570A (fr) 2020-05-20

Family

ID=63209687

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049570A MA49570A (fr) 2017-08-01 2018-07-31 Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak

Country Status (23)

Country Link
US (4) US10392368B2 (enExample)
EP (1) EP3652169A1 (enExample)
JP (2) JP7098716B2 (enExample)
KR (1) KR20200036004A (enExample)
CN (1) CN111032646B (enExample)
AR (1) AR112348A1 (enExample)
AU (1) AU2018312349A1 (enExample)
BR (1) BR112020002265A2 (enExample)
CA (1) CA3069990A1 (enExample)
CL (1) CL2020000283A1 (enExample)
CO (1) CO2020001469A2 (enExample)
EA (1) EA038912B1 (enExample)
IL (1) IL272031A (enExample)
MA (1) MA49570A (enExample)
MX (1) MX2020001170A (enExample)
MY (1) MY200629A (enExample)
PE (1) PE20201028A1 (enExample)
PH (1) PH12020500201A1 (enExample)
SG (1) SG11202000602YA (enExample)
TW (1) TW201920150A (enExample)
UA (1) UA125318C2 (enExample)
WO (1) WO2019027960A1 (enExample)
ZA (1) ZA202000561B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002265A2 (pt) 2017-08-01 2020-07-28 Theravance Biopharma R&D Ip, Llc compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase
JP2022518741A (ja) * 2019-01-23 2022-03-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ＪＡＫキナーゼ阻害剤としてのイミダゾ［１，５－ａ］ピリジン、１，２，４－トリアゾロ［４，３－ａ］ピリジンおよびイミダゾ［１，５－ａ］ピラジン
US20220257596A1 (en) * 2019-07-15 2022-08-18 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
AU2021252213A1 (en) * 2020-04-08 2022-11-03 Pfizer Inc. Crystalline forms of 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutaneacetonitrile, and use thereof
EP4149462A4 (en) 2020-05-14 2024-04-24 Theravance Biopharma R&D IP, LLC Administration of gut-selective jak3 inhibitor
WO2022033544A1 (zh) * 2020-08-13 2022-02-17 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN114075220A (zh) * 2020-08-13 2022-02-22 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN116157388A (zh) * 2020-09-10 2023-05-23 四川海思科制药有限公司 一种碳环酰胺衍生物及其在医药上的应用
WO2022199599A1 (zh) * 2021-03-23 2022-09-29 凯复(苏州)生物医药有限公司 丙烯酰基取代的化合物、包含其的药物组合物及其用途
WO2022212181A1 (en) * 2021-03-29 2022-10-06 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
CN113061137B (zh) * 2021-04-02 2022-08-02 广西医科大学 含氮杂环衍生物或其药学上可接受的盐和用途
IL308216A (en) * 2021-05-03 2024-01-01 Incyte Corp Jak1 pathway inhibitors for the treatment of prurigo nodularis
US20250051360A1 (en) * 2021-12-23 2025-02-13 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compound, and composition and use thereof
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444036A1 (en) 2001-04-20 2002-10-31 Yanfang Li Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP4810427B2 (ja) 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
CA2626579A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP1999135A2 (en) 2006-03-30 2008-12-10 Takeda San Diego, Inc. Kinase inhibitors
KR100834758B1 (ko) 2006-07-05 2008-06-05 삼성전자주식회사 컴퓨터 시스템 보안 장치 및 방법
JP2009007342A (ja) 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
ES2526966T3 (es) 2008-06-05 2015-01-19 Glaxo Group Limited Compuestos novedosos
JP2011529090A (ja) 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN103370076A (zh) 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102993201A (zh) * 2011-09-14 2013-03-27 赛诺菲 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3，4-b]吡啶-4-羧酸酰胺衍生物
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8993756B2 (en) * 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
TWI629275B (zh) 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
JP2016113366A (ja) * 2013-03-29 2016-06-23 大鵬薬品工業株式会社 アセトアミド基を有する１，２，４−トリアジン−６−カルボキサミド誘導体
MA39092B1 (fr) 2013-12-05 2018-09-28 Pfizer Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
WO2015112445A1 (en) 2014-01-24 2015-07-30 Abbvie Inc. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
ES2921874T3 (es) * 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
SG11201609139WA (en) 2014-05-14 2016-11-29 Pfizer Pyrazolopyridines and pyrazolopyrimidines
US10519160B2 (en) 2014-07-18 2019-12-31 The General Hospital Corporation Imaging agents for neural flux
US10590086B2 (en) 2014-11-03 2020-03-17 Iomet Pharma Ltd. Pharmaceutical compound
CN105837574B (zh) 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
EP3288943B1 (en) * 2015-05-01 2022-09-28 Pfizer Inc. Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
EP3291794A4 (en) 2015-05-07 2019-02-13 The Trustees of Columbia University in the City of New York PROCEDURE AND COMPOSITIONS FOR PROMOTING HAIR GROWTH
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN109311896B (zh) 2016-06-30 2021-08-24 株式会社大熊制药 吡唑并嘧啶衍生物作为激酶抑制剂
US9956158B2 (en) 2016-09-08 2018-05-01 Synergistic Therapeutics, Llc Topical hair growth formulation
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
US20180117148A1 (en) 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
KR102032418B1 (ko) * 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
BR112020002265A2 (pt) 2017-08-01 2020-07-28 Theravance Biopharma R&D Ip, Llc compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase
SG11202002947TA (en) 2017-11-03 2020-04-29 Aclaris Therapeutics Inc Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
TN2020000082A1 (en) 2017-12-28 2022-01-06 Dae Woong Pharma Oxy-fluoropiperidine derivative as kinase inhibitor
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
JP2022518741A (ja) * 2019-01-23 2022-03-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ＪＡＫキナーゼ阻害剤としてのイミダゾ［１，５－ａ］ピリジン、１，２，４－トリアゾロ［４，３－ａ］ピリジンおよびイミダゾ［１，５－ａ］ピラジン
EP4149462A4 (en) * 2020-05-14 2024-04-24 Theravance Biopharma R&D IP, LLC Administration of gut-selective jak3 inhibitor

Also Published As

Publication number Publication date
ZA202000561B (en) 2022-04-28
US20220119369A1 (en) 2022-04-21
US20190315724A1 (en) 2019-10-17
JP2021098751A (ja) 2021-07-01
EP3652169A1 (en) 2020-05-20
MY200629A (en) 2024-01-06
TW201920150A (zh) 2019-06-01
CO2020001469A2 (es) 2020-05-29
US10968205B2 (en) 2021-04-06
AU2018312349A1 (en) 2020-02-06
EA038912B1 (ru) 2021-11-09
KR20200036004A (ko) 2020-04-06
CA3069990A1 (en) 2019-02-07
IL272031A (en) 2020-03-31
US10392368B2 (en) 2019-08-27
CN111032646A (zh) 2020-04-17
UA125318C2 (uk) 2022-02-16
US20190040043A1 (en) 2019-02-07
PH12020500201A1 (en) 2020-10-12
CL2020000283A1 (es) 2020-06-12
AR112348A1 (es) 2019-10-16
BR112020002265A2 (pt) 2020-07-28
CN111032646B (zh) 2023-01-03
US20200216423A1 (en) 2020-07-09
WO2019027960A1 (en) 2019-02-07
JP2020529987A (ja) 2020-10-15
EA202090413A1 (ru) 2020-06-24
PE20201028A1 (es) 2020-10-05
JP7098716B2 (ja) 2022-07-11
SG11202000602YA (en) 2020-02-27
MX2020001170A (es) 2020-03-12
US10538513B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
MA53487A (fr) Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
FR22C1058I2 (fr) Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide
EP3596075C0 (en) AZAINDOLE AS INHIBITORS OF HPK1
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA50375A (fr) Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
EP3997087A4 (en) SUBSTITUTED CONDENSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THEIR USE
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
EP3328840A4 (en) SUBSTITUTED BICYCLIC TRIAZOL COMPOUNDS AS PDE2 INHIBITORS
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
DK3555097T3 (da) Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
CO2017005910A2 (es) Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens